48 This study generated great interest in metformin as an agent in cancer prevention and treatment, with many preclinical studies showing that metformin can inhibit the growth of cancer cells in vitro and in vivo.49–51 In parallel, a series of Tofacitinib alopecia observational studies conducted in various databases generally selleck chemicals reported similar beneficial results with metformin, thus “confirming” the findings of the 2005 study. A meta-analysis including some

of these observational studies reported that their combination resulted in a highly significant 31% reduction in cancer incidence or mortality associated with metformin use (RR 0.69; 95% CI 0.61–0.79).52 This convergence Inhibitors,research,lifescience,medical of evidence from multiple preclinical and epidemiological studies formed the impetus to recommend the conduct of randomized controlled trials (RCTs) Inhibitors,research,lifescience,medical of metformin in cancer prevention and treatment.53,54 There are currently many trials of this issue registered in clinicaltrials.gov. The many observational studies conducted to date will not be reviewed in detail here as they are the object of a separate paper.55 These observational studies have not only looked at whether Inhibitors,research,lifescience,medical metformin lowers cancer incidence and mortality,56–59 but also whether metformin can

act as a treatment of cancer to lower cancer mortality or recurrence.60 However, many of these observational studies that report significant reductions in cancer incidence and mortality and better prognosis with metformin Inhibitors,research,lifescience,medical use, with spectacular reductions ranging from 20% to 90%, are affected by time-related biases such as immortal time bias.34,35,55 This bias is known to exaggerate downward the effect of a drug, thus

making a drug appear protective when it in fact it may have no effect. On the other hand, two recent observational studies that specifically used the proper time-dependent statistical techniques Inhibitors,research,lifescience,medical to properly classify metformin exposure found no association between metformin use and cancer incidence.61,62 The first study used the GRPD and found a rate ratio of prostate cancer incidence of 1.23 Cilengitide (95% CI 0.99–1.52) with metformin use. With more than 36 prescriptions the rate ratio was in fact significantly elevated at 1.40 (95% CI 1.03–1.89).61 The second study used the Kaiser Permanente database and found no effect of metformin on the incidence of the 10 different cancers studied, with hazard ratios ranging between 0.8 (95% CI 0.6–1.1) for melanoma to 1.3 (95% CI 1.0–1.6) for kidney/renal pelvis.62 CONCLUSION Many observational studies conducted to uncover new indications for drugs that are already on the market have been shown to have major methodological flaws leading to important biases that tend to falsely suggest that a drug is highly effective.